News Recardio ceases UK drug trials, blaming Brexit Medical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit.
Events Partner Content SMi Presents the 13th Annual Conference: Parallel Trade 2019 parallel trade conference 2019
News Alnylam rare disease drug may be delayed Alnylam may have to put hold off plans for an early FDA approval for its gene-silencing drug givosiran – because recruitment to a rare disease trial is going better than expected.<
News Europe's CHMP regulatory committee has new chair Europe’s top drugs regulatory committee has a new leader after Dr Tomas Salmonson stepped down as chair of the CHMP after six years.
Events Partner Content Partnerships in Clinical Trials Europe | 27-29 November 2018... PCT: Let's Get Clinical
News Pharma outperforms academia at reporting clinical trials - B... Only half of trials reported results despite EU rules
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
